Immune evasion in human papillomavirus-associated cervical cancer

Nature Reviews Cancer

Volumn 2, Issue 1, 2002, Pages 59-65

  Tindle, Robert W ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; ONCOPROTEIN; VIRUS ANTIGEN; VIRUS PROTEIN; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ANIMAL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CODON; DENDRITIC CELL; FEMALE; GENE EXPRESSION REGULATION; GENETIC CODE; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSURVEILLANCE; KERATINOCYTE; MOLECULAR MIMICRY; MOUSE; PAPILLOMA VIRUS; PHYSIOLOGY; REVIEW; TRANSGENIC MOUSE; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS CAPSID; VIRUS CELL TRANSFORMATION; VIRUS INFECTION; ANTIBODY RESPONSE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CYTOKINE PRODUCTION; IMMUNE RESPONSE; LANGERHANS CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VIRUS REPLICATION; VIRUS STRAIN; WART VIRUS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, VIRAL; CAPSID; CELL TRANSFORMATION, VIRAL; CODON; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENETIC CODE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; INTERFERONS; KERATINOCYTES; MICE; MICE, TRANSGENIC; MOLECULAR MIMICRY; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS;

EID: 0036364468     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc700     Document Type: Review

References (47)

1. Zhou, J., Liu, W. J., Peng, S. W., Sun, X. Y. & Frazer, I. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J. Virol. 73, 4972-4982 (1999).
2. Schwartz, S. Regulation of human papillomavirus late gene expression. Ups. J. Med. Sci. 105, 171-192 (2000).
3. Nees, M. et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J. Virol. 75, 4283-4296 (2001).
4. Barnard, P., Payne, E. & McMillan, N. A. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-α. Virology 277, 411-419 (2000).
5. Park, J. S. et al. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 275, 6764-6769 (2000).
6. Arany, I., Goel, A. & Tyring, S. K. Interferon response depends on viral transcription in human papillomavirus containing lesions. Anticancer Res. 15, 2865-2870 (1995).
7. Rescigno, M. et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nature Immunol. 2, 361-367 (2001).
8. Li, M. et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J. Immunol. 166, 6099-6103 (2001).
9. Wolfers, J. et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nature Med. 7, 297-303 (2001).
10. Frazer, I. H. et al. Systemic administration of bacterial products induces host protective specific immunity to an epithelial tumour antigen. J. Immunol. 167, 6180-6187 (2001).
11. Doan, T. et al. Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. J. Virol. 73, 6166-6170 (1999).
12. Giannini, S. L. et al. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin. Exp. Immunol. 113, 183-189 (1998).
13. Geissmann, F. et al. TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162, 4567-4575 (1999).
14. Hemmi, H. et al. Skin antigens in the steady state are trafficked to regional lymph nodes by transforming growth factor-β1-dependent cells. Int. Immunol. 13, 695-704 (2001).
15. Hoffmann, T. K., Meidenbauer, N., Dworacki, G., Kanaya, H. & Whiteside, T. L. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 60, 3542-3549 (2000).
16. Albert, M. L., Jegathesan, M. & Darnell, R. B. Dendritic cell maturation is required for the cross-tolerization of CD8-T cells. Nature Immunol. 2, 1010-1017 (2001).
17. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160, 1212-1218 (1998).
18. Grohmann, U. et al. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J. Immunol. 166, 277-283 (2001).
19. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238 (2001).
20. Roncarolo, M. G., Levings, M. K. & Traversari, C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193, F5-F9 (2001).
21. Corinti, S., Albanesi, C., la Sala, A., Pastore, S. & Girolomoni, G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 166, 4312-4318 (2001).
22. Ressing, M. E. et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vitro and in vivo immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154, 5934-5943 (1995).
23. + T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter. J. Virol. 75, 5985-5997 (2001).
24. Lambrecht, B. N., Pauwels, R. A. & Fazekas De St Groth, B. Induction of rapid T cell activation, division, and recirculation by intratracheal injection of dendritic cells in a TCR transgenic model. J. Immunol. 164, 2937-2946 (2000).
25. Harshyne, L. A., Watkins, S. C., Gambotto, A. & Barratt-Boyes, S. M. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J. Immunol. 166, 3717-3723 (2001).
26. Natale, C., Giannini, T., Lucchese, A. & Kanduc, D. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol. Cell Biol. 78, 580-585 (2000).
27. Lee, S. J. et al. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-γ production in human peripheral blood mononuclear and NK cells. J. Immunol. 167, 497-504 (2001).
28. Le Buanec, H. et al. Induction of cellular immunosuppression by the human papillomavirus type 16 E7 oncogenic protein. Biomed. Pharmacother. 53, 323-328 (1999).
29. Cho, Y.-S. et al. Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18. FEBS Lett. 501, 139-145 (2001).
30. Straight, S. W., Herman, B. & McCance, D. J. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 69, 3185-3192 (1995).
31. + myeloid cells. J. Immunol. 166, 5398-5406 (2001).
32. Sheu, B. C. et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 61, 237-242 (2001).
33. Brady, C. S. et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55, 401-411 (2000).
34. Evans, M. et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J. Immunol. 167, 5420-5428 (2001).
35. Wang, S. S. et al. Human leucocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J. Infect. Dis. 184, 1310-1314 (2001).
36. Krul, E. J. T. et al. HLA susceptibility to cervical neoplasia. Hum. Immunol. 60, 337-342 (1999).
37. Sasaki, S., Amara, R. R., Oran, A. E., Smith, J. M. & Robinson, H. L. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases Nature Biotechnol. 19, 543-547 (2001).
38. Restifo, N. P. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr. Opin. Immunol. 12, 597-603 (2000).
39. Biragyn, A. & Kwak, L. W. Designer cancer vaccines are still in fashion. Nature Med. 6, 966-968 (2000).
40. Fabre, J. W. The allogeneic response and tumor immunity. Nature Med. 7, 649-652 (2001).
41. Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490 (2000).
42. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature 411, 380-384 (2001).
43. Muller, A., Schmitt, L., Raftery, M. & Schonrich, G. Paralysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction. Eur. J. Immunol. 28, 3488-3498 (1998).
44. Huang, H., Pan, X. & Zhou, J. BHRF1 antisense oligonucleotide inhibits anti-apoptosis of nasopharyngeal carcinoma cells. Int. J. Mol. Med. 4, 649-653 (1999).
45. Sette, A. D. et al. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. J. Immunol. 166, 1389-1397 (2001).
46. Anderson, C. C. et al. Testing time-, ignorance-, and danger-based models of tolerance. J. Immunol. 166, 3663-3671 (2001).
47. + cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J. Immunol. 161, 2421-2427 (1998).